Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 11/20 | 0.36 |
| ▸ | PRKDC | P78527 | 2/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.33 |
| ▸ | LDHB | P07195 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731377 | 0.73 | ATR (0.40) | PIK3CDPIK3CAPIK3CGATRPRKDC | |
| SCHEMBL19672862 | 0.68 | HSP90AA1 (0.51) | ATR | |
| SCHEMBL23732958 | 0.65 | ATR (0.32) | ATRPRKDC | |
| SCHEMBL14312975 | 0.64 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL3463003 | 0.62 | LDHA (0.58) | ATRLDHBMAP4K4LDHA | |
| SCHEMBL4783565 | 0.62 | PRKCI (0.43) | — | |
| SCHEMBL1166675 | 0.62 | ADORA2A (0.41) | — | |
| SCHEMBL840466 | 0.61 | ESR1 (0.39) | — | |
| SCHEMBL3124960 | 0.61 | ACHE (0.35) | — | |
| SCHEMBL1167036 | 0.61 | GSK3B (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008038010-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |